Halstead Michael 4
4 · Intra-Cellular Therapies, Inc. · Filed Feb 4, 2025
Insider Transaction Report
Form 4
Halstead Michael
SVP and General Counsel
Transactions
- Award
Restricted Stock Units
2025-02-03+45,454→ 45,454 total→ Common Stock (45,454 underlying) - Award
Common Stock
2025-01-31+11,017→ 11,017 total - Tax Payment
Common Stock
2025-01-31$127.00/sh−5,691$722,757→ 5,326 total
Footnotes (4)
- [F1]On March 10, 2022, the reporting person was granted performance-based restricted stock units ("PRSUs") under the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan. Each PRSU represents a contingent right to receive one share of common stock upon vesting and settlement. On January 31, 2025, 11,017 PRSUs were vested upon achievement of the reporting person's performance criteria.
- [F2]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the reporting person.
- [F3]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F4]On February 3, 2025, the reporting person was granted 45,454 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.